Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
A hypolipidemic agent from the group of fibroic acid derivatives. Reduces the blood levels of triglycerides and (to a lesser extent) - cholesterol. Helps reduce the content of VLDL, LDL (to a lesser extent), increase the content of anti-atherogenic HDL. The mechanism of action is not finally clarified. The effect at the TG level is mainly associated with the activation of the lipoprotein lipase enzyme. Apparently, fenofibrate also disrupts the synthesis of fatty acids; promotes an increase in the number of LDL receptors in the liver, disrupting the synthesis of cholesterol. Fenofibrate reduces platelet aggregation, reduces the elevated fibrinogen level in the plasma, can somewhat lower the blood glucose level in diabetic patients; reduces the level of uric acid in the blood.
PHARMACOKINETICS
After taking fenofibrate inside C max is reached within 5 hours. When taking 200 mg / day the average concentration in the plasma is 15 Ојg / ml. The value of C ss ismaintained throughout the treatment period. Binding to plasma proteins (albumin) is high. In tissues, fenofibrate is converted into an active metabolite, fenofibroic acid. Metabolised in the liver.
T 1/2 is 20 hours. It is excreted by the kidneys and through the intestine. Do not cumulate; not excreted by hemodialysis.
INDICATIONS
Hyperlipoproteinemia IIa, IIb, III and IV types, not amenable to diet correction.
DOSING MODE
Inside adults - 200-400 mg / day in 3 divided doses.
Preparations containing micronized fenofibrate are prescribed at the rate of 200 mg fenofibrate 1 time / day. Children - 5 mg / kg / day.
SIDE EFFECT
Possible: dyspeptic phenomena, increased activity of liver enzymes.
Rarely: myopathies, increased activity of CK, skin allergic reactions.
CONTRAINDICATIONS
Pronounced violations of the liver and kidneys, pregnancy, lactation (breastfeeding), children's age, hypersensitivity to fenofibrate.
PREGNANCY AND LACTATION
Fenofibrate is contraindicated for use in pregnancy and lactation (breastfeeding).
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe impairment of kidney function.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in severe violations of liver function.
APPLICATION FOR CHILDREN
Contraindicated in childhood.
SPECIAL INSTRUCTIONS
In the process of treatment with fenofibrate, systematic monitoring of the level of hepatic transaminases, blood coagulation indicators is necessary.
DRUG INTERACTION
With the simultaneous use of hypoglycemic agents with derivatives of sulfonylureas, there are reports of increased hypoglycemic effects.
With the simultaneous use of indirect anticoagulants (including acenocoumarol, warfarin), their effects are intensified. It is believed that fibrates increase the affinity of anticoagulants to the corresponding receptors or, possibly, disrupt their metabolism.
When used simultaneously with cyclosporine, kidney function may worsen and the concentration of cyclosporine in the blood plasma increase.
